---
aliases: [RVMD, Revolution]
---
#actor #company #biotech #oncology #usa #public

**Revolution Medicines** — RAS-targeted cancer therapies. Lead drug daraxonrasib in Phase 3 for pancreatic cancer. [[Nasdaq]]: RVMD. Potential $32B Merck acquisition target.

---

## Overview

| Metric | Value |
|--------|-------|
| Ticker | RVMD ([[Nasdaq]]) |
| Focus | RAS-addicted cancers |
| Stage | Late-stage clinical |
| Lead asset | Daraxonrasib (oral) |
| M&A status | In talks with [[Merck]] |

---

## Pipeline

| Drug | [[Target]] | Indication | Stage |
|------|--------|------------|-------|
| **Daraxonrasib** (RMC-6236) | Pan-RAS | Pancreatic, NSCLC | **Phase 3** |
| Elironrasib (RMC-6291) | G12C | NSCLC | Phase 2 |
| **Zoldonrasib** (RMC-9805) | G12D | NSCLC | Phase 2 (BTD) |
| RMC-5127 | G12V | Solid tumors | Phase 1 |

**RAS mutations:** Present in ~30% of all cancers. Historically "undruggable" until recent advances.

---

## Lead asset: Daraxonrasib

| Metric | Value |
|--------|-------|
| Type | Oral pan-RAS inhibitor |
| Trial | RASolute 302 (Phase 3) |
| Indication | 2L metastatic pancreatic cancer |
| Enrollment | Completing 2026 |
| Data readout | Expected 2026 |

**Keytruda combo:** 86% ORR with daraxonrasib + Keytruda in PD-L1 high patients. Front-line trial starting 2026.

---

## FDA Breakthrough Therapy (Jan 2026)

| Drug | Indication | Date |
|------|------------|------|
| Zoldonrasib | KRAS G12D NSCLC (2L+) | Jan 8, 2026 |

**First ever BTD for a G12D-targeted drug.**

---

## Merck acquisition talks (Jan 2026)

| Detail | Value |
|--------|-------|
| Buyer | [[Merck]] |
| Reported value | $28-32B |
| Rationale | Keytruda patent cliff (2028) |
| Context | Biggest biotech deal since Pfizer-Seagen ($43B) |

Merck CEO Mark Davis: Appetite for "multi tens of billions" in deals.

---

## Investment case

**Bull:**
- First-mover in RAS inhibition
- Multiple BTD designations
- Merck acquisition premium
- Keytruda combo synergies

**Bear:**
- Clinical trial execution risk
- Competition from other RAS programs
- Acquisition may not close

---

*Created 2026-01-17*

---

## Related

- [[Merck]] — potential acquirer
- [[Biopharma]] — sector
- [[Pfizer]] — Seagen deal comparison
- [[Keytruda]] — combo therapy partner
